In this video, Eleonora Teplinsky, MD, discusses results of the HER2CLIMB-05 study, showing that adding tucatinib to first-line maintenance therapy improved patient outcomes in HER2-positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results